Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $60.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).The analyst commented: "We're ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
